Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"... then it would be a great time to play green ... he nearly always left the casino a bit poorer than he went it ..."
Of course, he went home poorer ... he should have played black as there are many more black slots than green! 😉
Thanks, chrismiss. Does this denial mean Bio***t's chances in Asia, Africa, Australia and ROW are reduced to single digits for approval, i.e., only fda will approve its mab drugs?
If Bio***t has been asked, it would have PR'ed it.
One difference is that Anavex has been ASKED to file whereas Bio***t just filed.
George, you better start buying as it ain't going to happen unless you do. Expect AVXL stock price to close at or near the high of the day today on rather high buying volume.
Some hedge firms/MM must be worried about the growth side of Anavex's SP, such that, they brought Anshu2 back after 2+ months away (and probably from other assignments under another name(s)).
WOW! LTB, thanks for finding this and the same to TTT.
Now, for the peer review paper to be published.
george, you were only 4.3 MILLION SHORT on your prediction.
But still, george, there can't be a short squeeze if there are no sellers ... at $6 bucks or less.
So, who is selling 4 and a half million shares in ~ 15 minutes?
Anavex speakers @AAIC …
Has anyone heard either person speak? If so, how do their presentation skills compare to Dr. M?
TIA
vg, thank you. I can tell you two weeks ago, he and Hammonds were not listed in this section as the "About US" showed only 8 members, which is why I questioned whether he was still on the team with george.
Obviously, someone at Anavex reads this board and adjusted accordingly.
Once again, thanks, vg.
Wolf, Dr. Kaufmann is NOT and fda guy.
kevindallas, I'm not spinning anything. Why so many presentations in two days? Highly unusual for Anavex to allow any of its executives to present that much in such a short period of time. Dr. K is getting exposure there and not for Anavex, but for himself. He is the Rett fall guy in some people's eyes and I think Dr. M is allowing him to find another position in the best way possible ... by letting him tell as many people as possible what he knows in the pediatric neuro- world.
Also, why was he removed from the list of senior executives on the Company's web page? No reason to do so as there is plenty of space.
To me, these are indications, he is moving on.
P.S. That is my opinion, george, even though he has Anavex titles.
So, why is Dr. Kaufman making 4 presentations in two days, when he hasn't done that many in all the time he's been with Anavex? Plus, one presented a few weeks ago re: Rett.
IMO, he is looking ... goes with removal from Company web site of the top dogs.
Seems WS/MM are pushing our competitors, SAVA and ANVS, higher (regardless of their drugs' woes) and concluding that Anavex's top has been reached for the day, if not the week.
Thanks to those who note the continued manipulation ... Beers on me. 🍻
It will go into the trash bin as "Dismissed with prejudice!"
george, you should include the presenter's name, too, when you re-post it. This indicates some progress in the ranks at Anavex.
TIA
george, why can't you accept an opinion that is different than yours and let it GO! ... as opposed to yelling "WRONG!!!" at the top of your lungs.
For the value you bring, you tarnish it when you respond that way, which seems to be happening more recently.
Peace,
powerwalker
george, please note on slide 11, Blarcamesine is shown as a non-descripted pill. So, slide 25 is only a presentation-highlighted photo, and not how it is going to be marketed and sold, IMO.
Steady, I agree with you that 2-73 will be approved for Rett.
My apology for using the word "tied."
After the market tomorrow, Hoskuld ... no PM, too.
Hoskuld, in reading the announcement, I'm surprised it did not double before that weekend. Agree with your assessment of its potential.
Somebody held it down for the obvious reasons, IMO.
P.S. Investor, wasn't it Steady who was tied to Excellence?
Thanks, William. 👍️
Who are the weak hands that are selling in the $4.90's. Have some cajones, at least, and ask for 5 BUCKS!
SMH ... don't they know Anavex is increasing in SP!!
Thanks, John.
Hosai, thanks for the FB info.
Does it state that he is still CMO @ Anavex?
TIA
In NY Times this AM: Children With Autism Carry Unique Gut Flora, Study Finds
https://www.nytimes.com/2024/07/08/health/autism-gut-microbiome.html?campaign_id=9&emc=edit_nn_20240709&instance_id=128273&nl=the-morning®i_id=133992977&segment_id=171652&te=1&user_id=e69e099151d6292f15cad9f830459850
DFRAI, thanks for the article though far above my understanding.
Is Nature setting up its readers for the Anavex peer review article with this Sigma 1 piece (and others it has printed)?
Time will tell.
See the 8-K filed with SEC.
Thanks, Bar.
Here is the web site's listing of open positions. It appears to be the same list from a year ago plus, though a few positions have been filled.
You would think someone would be assigned to keep this current!! Pathetic!!
https://www.anavex.com/job-opportunities
Current Job Openings
Biostatistics Associate Director/Director/Senior Director
Clinical Data Associate
Clinical Development & Medical Evidence, Senior/Exective Director
Clinical Development, Director/Senior Director/Executive Director
Clinical Operations, Sr. Director/Director/ Associate Director
Clinical Trial Operations, Senior Clinical Trial Associate/Clinical Trial Associate
Data Programmer
Global Pharmacovigilence, Senior/Executive Director
Head of Research & Development
Quality Assurance, Associate Director or Senior Manager
SAS Programmer
Whatever! I think my point has been made.
Sorry, chrismiss, we need more info and details, as in a link or two.
TIA
george, if it didn't, why isn't 2-73 Plus the drug in trial? The 2-73 Plus/2-73+DPZ did not help those taking it in the P2a trial. The only participants that improved were those on 2-73 only. When donepezil occupies the sigma-1 receptor site it blocks blarcamesine.
P.S. Per you:
Isn't that "OVERWHELM?"
Excuse my language, but you know damn well that 2-73 + DPZ, a/k/a 2-73 Plus, does NO good for the patient. DPZ overwhelms 2-73 such that 2-73 has no impact . We have known this for many years.
Nice try at obfuscation, Investor ... but why should we think you have changed and would want 2-73 to be successful!
Investor, from an earlier post regarding P2b/3 AD trial, it was noted that the placebo is DPZ. So, we will learn "soon" how 2-73 vs. DPZ fight turns out.
I think we both want to see a 2-73 "KO!"
That's me! ✋️
EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States.
Reading the first line:
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-approves-sanofis-dupixent-smokers-lungs-2024-07-03/
Early on, Merck, Lundbeck and Takeda were willing to join Anavex in the Consortium as each perceive some value in 2-73..
Those three companies (and others in the Consortium) will be rewarded for their foresight in the long run.
Wolf, I read this AM and did not see any "p" values. That is why I was not surprised ANVS was down early. Non-event, it seemed.
WS and MM's must have pushed it for new financing coming.
Did you see a "p" value?